125 related articles for article (PubMed ID: 38372034)
1. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer.
Lai SP; Wang SY; Chan AL; Leung JH; Yip HT
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):541-549. PubMed ID: 38372034
[TBL] [Abstract][Full Text] [Related]
2. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Mehta DA; Hay JW
Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
[TBL] [Abstract][Full Text] [Related]
4. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
9. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
Chappell NP; Miller CR; Fielden AD; Barnett JC
J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
[TBL] [Abstract][Full Text] [Related]
10. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38186268
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
[TBL] [Abstract][Full Text] [Related]
18. First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
Neyt M; Vlayen J; Devriese S; Camberlin C
PLoS One; 2018; 13(4):e0195134. PubMed ID: 29630612
[TBL] [Abstract][Full Text] [Related]
19. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]